GlassScriptPhysician profile
Florencio V Llacuna
NPI 1710047733
$6,172.15
in general payments reported to CMS, 2019-2025
24 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $880 · 2021: $755 · 2022: $1,047 · 2023: $1,212 · 2024: $1,010 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,476.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $698.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.46 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $492.49 | 2022-2024 | |
| Abbott Laboratories | $455.61 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $365.36 | 2020-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $353.99 | 2019-2025 | Capvaxive |
| Amgen INC. | $347.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $245.72 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $210.45 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.09 | 2019-2023 | Cycloset |
| Dexcom, INC. | $139.66 | 2021-2023 | Dexcom G6 Transmitter |
| Philips North America LLC | $107.23 | 2022 | |
| Allergan, INC. | $87.56 | 2019-2020 | |
| Amarin Pharma, INC. | $81.75 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $69.57 | 2019-2024 | Livalo |
| Astrazeneca Pharmaceuticals LP | $63.29 | 2019-2023 | Farxiga |
| Azurity Pharmaceuticals, INC. | $52.38 | 2023 | Edarbi |
| Glaxosmithkline, LLC. | $43.96 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $41.25 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $30.52 | 2022-2023 | Jynarque |
| Corcept Therapeutics | $28.34 | 2024 | Korlym |
| Hikma Pharmaceuticals USA | $12.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florencio Llacuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.